ACDIMA

What ACDIMA does

ACDIMA (The Arab Company for Drug Industries and Medical Appliances) is a Jordan-headquartered, non-profit Arab institution focused on the pharmaceutical and medical appliances sector, founded in 1976 and operating with 101–250 employees. Its stated remit is to set strategy for the drug industry and medical appliances across the Arab region. Detailed product portfolio, operating metrics, and revenue mechanics are not disclosed in available sources; the company's website was inaccessible during data collection.

Operationally, ACDIMA functions in significant part as a strategic equity holder in regional pharmaceutical companies. Its most material disclosed asset is a stake in SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), where it held approximately 20.5% prior to a July 2026 transaction. On 22 July 2026, ACDIMA divested roughly 10% of SPIMACO (11,998,000 shares) for SAR 326.34 million (~$87 million) to two funds managed by Alistithmar Capital (a subsidiary of the Saudi Investment Bank), with GIB Capital acting as financial advisor. Post-transaction, ACDIMA retained a 10.5% stake in SPIMACO, preserving a continuing cross-border Arab institutional position within the Saudi pharmaceutical ecosystem.

The source data does not disclose ACDIMA's revenue model, pricing, customer base, geographic operating footprint beyond the Amman headquarters, leadership team, or any AI/technology capabilities. As such, while the SPIMACO divestment provides a clear capital-event data point, the underlying commercial engine of the institution cannot be characterized from available evidence and remains a key analytical gap.

Name

ACDIMA

Legal name

The Arab Company for Drug Industries and Medical Appliances

Website

https://acdima.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

51–100 employees

Short description

ACDIMA is a Jordan-based, non-profit Arab institution founded in 1976 that supports the pharmaceutical and medical appliances sector across the region, and currently acts as a strategic equity holder in companies such as SPIMACO.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Management of Companies and Enterprises (5511)

SIC

Pharmaceutical Preparations (2834), International Affairs (9721)

akta.pro industry

PRIMARYHLAJAOAK

Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

Keywords

• Pharmaceutical manufacturing
• Drug industry strategy
• Medical appliances production
• Arab pharmaceutical institution
• Pharmaceutical investment holding

Headquarters

HQ city

Amman

HQ country

Jordan

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Core offering

ACDIMA (The Arab Company for Drug Industries and Medical Appliances) is an Arab institution that sets up strategy for the drug industry and medical appliances sector. It operates in pharmaceutical manufacturing and distribution and acts as a strategic investor in pharmaceutical companies, including a retained 10.5% stake in SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation) following a 2026 divestment.

Product overview

ACDIMA (The Arab Company for Drug Industries and Medical Appliances) is a pharmaceutical company. Based on available sources, the company is primarily known as an investor/holder in pharmaceutical companies including SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), in which it retained a 10.5% stake following a recent divestment. The website was inaccessible during data collection, limiting detailed product portfolio information.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Products

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights2 records

Regional players

• Gulf Pharmaceutical Industries (Julphar): Julphar is a UAE-based generics manufacturer with a regional MENA footprint, serving similar pharmaceutical end-markets as ACDIMA's investee ecosystem. It is a useful regional peer for understanding Gulf pharma manufacturing economics and competitive dynamics.
• Pharco Pharmaceuticals: Pharco is a major Egyptian pharma group covering generics, biopharma, and healthcare services. It represents another large-scale Arab pharma manufacturer comparable to ACDIMA's strategic coordination role and investee base.
• Egyptian International Pharmaceutical Industries (EIPICO): EIPICO is one of the largest Egyptian pharmaceutical manufacturers with a broad branded-generics portfolio. It serves as a North African peer comparable to ACDIMA's strategic mandate across the Arab pharmaceutical sector.
• Tabuk Pharmaceuticals: Tabuk is a Saudi-headquartered pharma manufacturer with branded generics, APIs, and consumer health operations. It operates in the same Saudi pharmaceutical ecosystem as ACDIMA's investee SPIMACO and is a relevant regional comparable for portfolio strategy.

Broad incumbents

• Cipla: Cipla is an Indian multinational pharma major with deep MENA distribution and partnership presence. Its emerging-markets franchise, branded-generics orientation, and MENA go-to-market overlap make it a relevant broader peer.
• Aspen Pharmacare: Aspen is a South African-headquartered global specialty generics and branded pharma group with significant emerging-markets exposure. It is an emerging-markets pharma peer useful for benchmarking ACDIMA's strategic-stake model in a publicly-listed format.
• Hikma Pharmaceuticals: Hikma is a Jordan-headquartered (same home country as ACDIMA) multinational generics and specialty pharma company. As the leading Jordanian-origin pharma platform with broad MENA and global reach, it is a natural peer for evaluating ACDIMA's strategic mandate and regional pharma positioning.

Direct peers

• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): SPIMACO is ACDIMA's principal investee and direct strategic counterpart in Saudi pharma manufacturing. ACDIMA retains a 10.5% stake post-July 2026 divestment, making SPIMACO the closest operating analogue to ACDIMA's strategic exposure in branded generics and medical appliances.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/Acdimajo
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/acdima

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACDIMA